Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON31666
NL-OMON31666
Withdrawn
Not Applicable

Dopaminergic neurotransmission and cognitive decline in velocardiofacial syndrome - Dementia in VCFS

Academisch Medisch Centrum0 sites40 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscognitive declinedementia10083624

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
cognitive decline
Sponsor
Academisch Medisch Centrum
Enrollment
40
Status
Withdrawn
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Possession of del 22q11\.2
  • •Premorbid IQ of above 70 en now below 55
  • •Premorbid IQ below 55
  • •Only for the intervention group: serious behavioural and/or refractory psychiatric problems to treatment so far

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Dopaminergic neurotransmission and cognitive decline in velocardiofacial syndrome - Dementia in VCFSDementia in velocardiofacial syndromeMedDRA version: 8.1Level: LLTClassification code 10012267Term: Dementia
EUCTR2006-006203-36-NLAcademic Medical Centre (AMC)
Completed
Not Applicable
Dopaminergic neurotransmission and cognitive deterioration in velocardiofacial syndrome
NL-OMON33641Medisch Universitair Ziekenhuis Maastricht44
Not yet recruiting
Not Applicable
Het dopamine systeem en cognitieve achteruitgang bij patiënten met VCFS.velocardiofacial syndromedel22q11.2dementiadementievelocardiofaciaal syndroom
NL-OMON26307Governor Kremers Centre / Department of Clinical GeneticsMaastricht, the Netherlands44
Recruiting
Not Applicable
Dopaminergic modulation of cognition and psychomotor functiogeen aandoeningnot applicable
NL-OMON38372niversiteit Maastricht30
Active, not recruiting
Not Applicable
Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratamiento con levodopa.Fluctuaciones motoras, cognitivas y del humor en la enfermedad de Parkinson.MedDRA version: 8.1Level: PTClassification code 10061536Term: Parkinson's disease
EUCTR2006-002408-32-ESInstitut de Recerca del Hospital de la Santa Creu i Sant Pau20